Dr. Charles Wykoff of Retinal Consultants of Houston joins Jay to discuss the recently presented 2-year results of Regeneron's PANORAMA study of anti-VEGF for moderately severe and severe nonproliferative diabetic retinopathy.
Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Alimera, Regeneron and Oxurion. Dr. Wykoff's relevant disclosures include consultant/speaker/research funding from Allergan, Genentech, Novartis and Regeneron, and consultant/research funding from Bayer and Roche.
CME Information
Release: March 22, 2020; expires March 22, 2023
Reviewers: Purnima Patel, MD; Shriji Patel, MD; Carl Danzig, MD
Disclosures: The physician reviewers and Academy staff report no relevant financial disclosures.
Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for the management of vitreoretinal disorders or the outcomes from recent research and how these impact patient care decisions.
Audience: This activity is intended for retina subspecialists and comprehensive ophthalmologists.
Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.